<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218958</url>
  </required_header>
  <id_info>
    <org_study_id>ALK21-003</org_study_id>
    <nct_id>NCT01218958</nct_id>
  </id_info>
  <brief_title>ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted
      in subjects diagnosed with alcohol dependence as defined by the Diagnostic and Statistical
      Manual of Mental Disorders, 4th Ed. (DSM-IV). Subjects were randomized (2:2:1:1) to receive
      intramuscular (IM) injections of Medisorb® naltrexone 190 mg, Medisorb naltrexone 380 mg,
      placebo for Medisorb naltrexone 190 mg, or placebo for Medisorb naltrexone 380 mg
      (VIVITROL®). Study drug was administered every 4 weeks for a total of 6 injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects received standardized biopsychosocial support therapy (BRENDA Approach
      [Volpicelli, JR [2001]; Guilford Press: New York]) at each visit.

      Subjects who completed this study (ie, received 6 injections of study drug and completed all
      study visits) and continued to meet eligibility criteria were given the option to enroll in
      extension study ALK21-003EXT (NCT01218971). A second extension, Study ALK21-010
      (NCT00156923), was conducted subsequent to ALK21-003EXT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Heavy Drinking Days Over the Treatment Period</measure>
    <time_frame>Baseline through Week 24 (168 days)</time_frame>
    <description>Drinking rates were assessed from participants' self-reports using the validated Timeline Follow-Back (TLFB) method. Using a TLFB calendar, participants reported the number of days they had consumed alcohol along with the amount they consumed on each day. A heavy drinking day was defined as ≥5 drinks/day for men and ≥4 drinks/day for women.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>24 weeks (Baseline to Week 24)</time_frame>
    <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">624</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Medisorb naltrexone 190 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medisorb naltrexone 380 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Medisorb naltrexone 190 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Medisorb naltrexone 380 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medisorb naltrexone 190 mg</intervention_name>
    <description>Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.</description>
    <arm_group_label>Medisorb naltrexone 190 mg</arm_group_label>
    <other_name>naltrexone for extended-release injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medisorb naltrexone 380 mg</intervention_name>
    <description>IM injection once every 4 weeks for a total of 6 administrations.</description>
    <arm_group_label>Medisorb naltrexone 380 mg</arm_group_label>
    <other_name>VIVITROL 380 mg</other_name>
    <other_name>naltrexone for extended-release injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Medisorb naltrexone 190 mg</intervention_name>
    <description>IM injection once every 4 weeks for a total of 6 administrations.</description>
    <arm_group_label>Placebo for Medisorb naltrexone 190 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Medisorb naltrexone 380 mg</intervention_name>
    <description>IM injection once every 4 weeks for a total of 6 administrations.</description>
    <arm_group_label>Placebo for Medisorb naltrexone 380 mg</arm_group_label>
    <other_name>Placebo matching VIVITROL 380 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Diagnosis of alcohol dependence based on Diagnostic and Statistical Manual of Mental
             Disorders, 4th Ed. (DSM-IV) criteria

          -  Male or non-pregnant, non-lactating female

          -  Able to provide TimeLine Follow-Back (TLFB) alcohol consumption information for 90-day
             period before detoxification and/or screening

          -  At least 2 episodes of heavy alcohol drinking per week during the 30 days before
             detoxification and/or screening

          -  Negative urine toxicological screen for opiates on day of randomization

          -  Noncustodial, stable residence and phone plus 1 contact with verifiable address and
             phone

        Primary Exclusion Criteria:

          -  Evidence of hepatic failure including: ascites, prolonged prothrombin time (PT)
             (international normalized ratio [INR] ≥1.7), bilirubin &gt;10% above upper limit of
             normal (ULN) and/or esophageal variceal disease

          -  Active hepatitis and/or aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) higher than 3xULN

          -  History of pancreatitis

          -  Major depression with suicidal ideation, psychosis, bipolar disorder, or psychiatric
             disorders that would compromise subject's ability to complete the study

          -  Current dependence (within past year) per DSM-IV criteria to benzodiazepines, opioids
             or cocaine

          -  Use of benzodiazepines and/or Ambien® (zolpidem tartrate) within 7 days prior to first
             dose of study medication

          -  Greater than 7 days inpatient treatment for substance use disorders within 30 days of
             randomization

          -  Use of any opioids and/or methadone within 14 days of screening, or likely requiring
             opioid therapy during study period

          -  Use of oral naltrexone or disulfiram within 14 days of screening

          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or
             polylactide-co-glycolide (PLG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005 Apr 6;293(13):1617-25. Erratum in: JAMA. 2005 Apr 27;293(16):1978. JAMA. 2005 Jun 15:293(23):2864.</citation>
    <PMID>15811981</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol. 2007 Oct;27(5):507-12.</citation>
    <PMID>17873686</PMID>
  </results_reference>
  <results_reference>
    <citation>Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat. 2007 Jul;33(1):71-80. Epub 2007 Feb 22. Review.</citation>
    <PMID>17588491</PMID>
  </results_reference>
  <results_reference>
    <citation>Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008 Mar;32(3):498-504. doi: 10.1111/j.1530-0277.2007.00593.x. Epub 2008 Jan 30.</citation>
    <PMID>18241321</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM. Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry. 2008 Feb;69(2):190-5.</citation>
    <PMID>18348601</PMID>
  </results_reference>
  <results_reference>
    <citation>Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O'Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res. 2009 Feb;33(2):350-6. doi: 10.1111/j.1530-0277.2008.00843.x. Epub 2008 Nov 25.</citation>
    <PMID>19053979</PMID>
  </results_reference>
  <results_reference>
    <citation>Lapham S, Forman R, Alexander M, Illeperuma A, Bohn MJ. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients. J Subst Abuse Treat. 2009 Jan;36(1):1-6. doi: 10.1016/j.jsat.2008.07.001. Epub 2008 Sep 4.</citation>
    <PMID>18775624</PMID>
  </results_reference>
  <results_reference>
    <citation>Cisler RA, Silverman BL, Gromov I, Gastfriend DR. Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence. J Addict Med. 2010 Sep;4(3):181-5. doi: 10.1097/ADM.0b013e3181c82207.</citation>
    <PMID>21769033</PMID>
  </results_reference>
  <results_reference>
    <citation>Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.</citation>
    <PMID>21575016</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>November 5, 2010</results_first_submitted>
  <results_first_submitted_qc>November 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2010</results_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <name_title>Bernard Silverman, MD, Vice President, Clinical Development</name_title>
    <organization>Alkermes, Inc.</organization>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential subjects were screened up to 14 days before administration of study drug (Study Day 0).</recruitment_details>
      <pre_assignment_details>A dynamic randomization was implemented to optimize balancing treatment assignment for 4 prespecified factors: gender, subject's baseline goal of abstinence (ie, yes/no), presence of abstinence prior to randomization, and study site.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Medisorb Naltrexone 190 mg</title>
        </group>
        <group group_id="P2">
          <title>Medisorb Naltrexone 380 mg</title>
        </group>
        <group group_id="P3">
          <title>Placebo Groups (Pooled)</title>
          <description>Results for the two groups that received placebo were pooled together for reporting purposes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medisorb Naltrexone 190 mg</title>
        </group>
        <group group_id="B2">
          <title>Medisorb Naltrexone 380 mg</title>
        </group>
        <group group_id="B3">
          <title>Placebo Groups (Pooled)</title>
          <description>Results for the two groups that received placebo were pooled together for reporting purposes.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
            <count group_id="B2" value="205"/>
            <count group_id="B3" value="209"/>
            <count group_id="B4" value="624"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="602"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="10.8"/>
                    <measurement group_id="B2" value="45.0" spread="10.1"/>
                    <measurement group_id="B3" value="44.7" spread="10.8"/>
                    <measurement group_id="B4" value="44.7" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Heavy Drinking Days Over the Treatment Period</title>
        <description>Drinking rates were assessed from participants' self-reports using the validated Timeline Follow-Back (TLFB) method. Using a TLFB calendar, participants reported the number of days they had consumed alcohol along with the amount they consumed on each day. A heavy drinking day was defined as ≥5 drinks/day for men and ≥4 drinks/day for women.</description>
        <time_frame>Baseline through Week 24 (168 days)</time_frame>
        <population>The last post-baseline observation carried forward (LOCF) of each participant in the intent-to-treat population (all randomized participants who received at least 1 injection of study drug) were utilized for the primary efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Medisorb Naltrexone 190 mg</title>
          </group>
          <group group_id="O2">
            <title>Medisorb Naltrexone 380 mg</title>
          </group>
          <group group_id="O3">
            <title>Placebo Groups (Pooled)</title>
            <description>Results for the two groups that received placebo were pooled together for reporting purposes.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Heavy Drinking Days Over the Treatment Period</title>
          <description>Drinking rates were assessed from participants' self-reports using the validated Timeline Follow-Back (TLFB) method. Using a TLFB calendar, participants reported the number of days they had consumed alcohol along with the amount they consumed on each day. A heavy drinking day was defined as ≥5 drinks/day for men and ≥4 drinks/day for women.</description>
          <population>The last post-baseline observation carried forward (LOCF) of each participant in the intent-to-treat population (all randomized participants who received at least 1 injection of study drug) were utilized for the primary efficacy analysis.</population>
          <units>Percentage of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Days</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="204"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.75" lower_limit="3.23" upper_limit="44.58"/>
                    <measurement group_id="O2" value="10.23" lower_limit="1.16" upper_limit="33.33"/>
                    <measurement group_id="O3" value="19.77" lower_limit="6.01" upper_limit="50.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The event rate (percentage) is represented by the number of heavy drinking days divided by number of days at risk. For each day, the active groups' results were contrasted with placebo to form the event rate ratio. Thus, a hazard ratio of 0.75 for the 380 mg group indicates a 25% reduction in heavy drinking compared with that of placebo.
The method of analysis estimates the average ratio over time and accounts for discontinuation. Point/interval estimates for pairwise ratios were derived.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0245</p_value>
            <p_value_desc>The Hochberg method was used to adjust P-value for multiple comparisons (ie, 380 mg dose vs. placebo and 190 mg dose vs. placebo).</p_value_desc>
            <method>Andersen-Gill recurrent-event Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.751</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.600</ci_lower_limit>
            <ci_upper_limit>0.940</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0744</p_value>
            <method>Andersen-Gill recurrent-event Cox model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.830</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.677</ci_lower_limit>
            <ci_upper_limit>1.018</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE)</title>
        <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
        <time_frame>24 weeks (Baseline to Week 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medisorb Naltrexone 190 mg</title>
          </group>
          <group group_id="O2">
            <title>Medisorb Naltrexone 380 mg</title>
          </group>
          <group group_id="O3">
            <title>Placebo Groups (Pooled)</title>
            <description>Results for the two groups that received placebo were pooled together for reporting purposes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE)</title>
          <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="187"/>
                    <measurement group_id="O3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events were recorded starting at baseline through 42 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medisorb Naltrexone 190 mg</title>
        </group>
        <group group_id="E2">
          <title>Medisorb Naltrexone 380 mg</title>
        </group>
        <group group_id="E3">
          <title>Placebo Groups (Pooled)</title>
          <description>Results for the two groups that received placebo were pooled together for reporting purposes.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 4.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Inflammatory carcinoma of the breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Psychotic disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilic pneumonia acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 4.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="181" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite decreased NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Anxiety NEC</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard L. Silverman, VP, Clinical Development</name_or_title>
      <organization>Alkermes, Inc.</organization>
      <phone>781-609-6000</phone>
      <email>bernard.silverman@alkermes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

